SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-014316
Filing Date
2024-02-15
Accepted
2024-02-15 08:00:24
Documents
14
Period of Report
2023-09-06
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea193846-8ka1_cadrenal.htm   iXBRL 8-K/A 30231
  Complete submission text file 0001213900-24-014316.txt   207916

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cvkd-20230906.xsd EX-101.SCH 3015
3 XBRL LABEL FILE cvkd-20230906_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE cvkd-20230906_pre.xml EX-101.PRE 22359
15 EXTRACTED XBRL INSTANCE DOCUMENT ea193846-8ka1_cadrenal_htm.xml XML 4072
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

IRS No.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41596 | Film No.: 24642167
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)